Biogen 3Q 2026: Revenue $2.8B, Net income ($20.6M), EPS ($0.14) — 10-Q Summary

What happened

Biogen reported third-quarter 2026 revenue of $2.8B, up 10.6% from a year earlier, while recording a net loss of $20.6M and diluted EPS of ($0.14), compared with net income of $466.5M and EPS of $3.17 in the prior-year quarter.

Confirmed

Global impact / market context

Revenue growth did not translate into profit: rare disease and immunology sales rose, but multiple sclerosis sales fell 13.4% and the May Apellis acquisition added costs. That gap between sales and profit helps explain why the quarter produced a net loss for investors.

Analyst inference

Biogen is shifting its product mix: rare disease revenue grew 26.8% and ZURZUVAE rose 52.6%, while older multiple sclerosis drugs face generics and falling demand. Integration and cost savings from the Apellis deal now matter for whether revenue growth converts into profit.

Analyst inference

What to watch

1. Biogen said it expects multiple sclerosis revenue to keep declining, so watch whether rare disease and immunology growth can offset that drop and support total revenue next quarter. Confirmed
2. Watch progress on Apellis integration and cost-synergy efforts, which means combining operations and cutting duplicate costs, plus sales of SYFOVRE and EMPAVELI, which generated $242.8M combined U.S. third-quarter sales. Proposed
3. Watch whether high-dose SPINRAZA approvals and the planned Phase 3 development of diranersen, an experimental drug, can strengthen rare disease revenue enough to improve profit per sale and return the company to net income. Analyst inference

Evidence

• Original source link unavailable